Results 71 to 80 of about 16,284 (266)
Frontiers in Pharmacology, 2011 Receptors for sphingosine-1-phosphate (S1P) have been identified only recently. Their medicinal chemistry is therefore still in its infancy, and few selective agonists or antagonists are available. Furthermore, the selectivity of S1P receptor agonists or
Christian eWaeber, Salvatore eSalomone
doaj +1 more source
Exploration, EarlyView.Selenium (Se) is a crucial element in selenoproteins, key biomolecules for physiological function in vivo. Central nervous system can express all 25 kinds of selenoproteins, which protect neurons by reducing oxidative stress and inflammatory response. Neuroprotection is being investigated through the biological study of Se.
Guanning Huang +4 more
wiley +1 more source
Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension
Respiratory Research, 2011 Background Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Brandes Ralf P +13 more
doaj +1 more source
The Discovery of Nonpeptide Endothelin Receptor Antagonists. Progression towards Bosentan
CHIMIA, 1996 Since its discovery, endothelin-1 has attracted considerable scientific interest for its extremely potent and long-lasting vasoconstrictor effect and its binding to G-protein-coupled receptors.
Werner Neidhart +8 more
doaj +2 more sources
Molecular Nutrition &Food Research, EarlyView.(Poly)phenols constitute a source of natural therapeutic molecules capable of targeting angiogenesis in different scenarios. This review summarizes the current evidence of the role of (poly)phenols in modulating angiogenesis. The reader can find a compilation of preclinical and human investigations describing pro‐ and anti‐angiogenic effects of these ...
María Ángeles Ávila‐Gálvez +5 more
wiley +1 more source
Evidence for biased agonists and antagonists at the endothelin receptors
Life Sciences, 2016 Biased ligands represent a new strategy for the development of more effective and better tolerated drugs. To date there has been a paucity of research exploring the potential of ligands that exhibit either G protein or β-arrestin pathway selectivity at the endothelin receptors.
openaire +3 more sources
Pharmacotherapy for Cirrhosis in Japan
Portal Hypertension &Cirrhosis, EarlyView.As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley +1 more source
Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? [PDF]
Nephrology (Carlton), 2023 Chung EYM +3 more
europepmc +1 more source
Endothelin receptor antagonists in pulmonary arterial hypertension
Journal of the American College of Cardiology, 2004 Endothelin receptor antagonism has emerged as an important therapeutic strategy in pulmonary arterial hypertension (PAH). Laboratory and clinical investigations have clearly shown that endothelin (ET)-1 is overexpressed in several forms of pulmonary vascular disease and likely plays a significant pathogenetic role in the development and progression of ...
Robyn J. Barst +4 more
openaire +3 more sources
Rare but relevant: The injection of tablet preparations and pulmonary hypertension
Addiction, Volume 120, Issue 6, Page 1276-1279, June 2025.Abstract Intravascular injection of dissolved medicinal preparations such as crushed tablets is associated with a risk of injecting particulate material into the vasculature. This particulate material will naturally pass to the lungs where it will be largely filtered out in the pulmonary vascular bed, and in turn, it can result in a range of ...
Johan Duflou
wiley +1 more source